

TABLE OF CONTENTS

Cardiology I	1
Cardiology I Panel	3
 Heart Failure with Reduced Ejection Fraction	
 <i>By Ralph J. Riello III, Pharm.D., BCPS</i>	
Introduction	7
HF Updates According to the 2021 Expert Consensus Decision Pathway	9
Optimizing GDMT	15
Inotropic Therapy	17
Advanced Therapeutic Modalities	21
Heart Failure with Preserved Ejection Fraction	23
Conclusion	25
References	25
Self-Assessment Questions	29
 Drug-Induced Cardiovascular Disease	
 <i>By Katherine Aymond, Pharm.D., BCPS, BCCP</i>	
Introduction	33
Chemotherapy and Immunotherapy-Induced Cardiotoxicity	33
Other Agents of Cardiotoxicity	42
Conclusion	51
References	51
Self-Assessment Questions	53
 Cardiology II	57
Cardiology II Panel	59
 Peripheral Arterial Disease	
 <i>By Anastasia L. Armbuster, Pharm.D., FACC, BCPS, BCCP</i>	
Introduction	63
Diagnosis	65
Pharmacotherapy in Patients with PAD	66
Symptomatic Management	71
Critical Limb Ischemia	72
Acute Limb Ischemia	73
Conclusion	75
References	76
Self-Assessment Questions	79
 Antithrombotic Therapy in Cardiac Interventions	
 <i>By Stephanie Dwyer Kaluzna, Pharm.D., BCCP; and Jaclynne Gowen, Pharm.D., BCCP</i>	
Percutaneous Coronary Intervention	83
Use of P2Y ₁₂ Inhibitor in Percutaneous Coronary Intervention	85
Triple Antithrombotic Therapy	98
Antithrombotic Therapy in Transcatheter Aortic Valve Implantation	103
Antithrombotic Therapy in MitraClip	105
Conclusion	107
References	108
Self-Assessment Questions	111
 Cardiology III	115
Cardiology III Panel	117
 Management of Atrial Fibrillation	
 <i>By Amy L. Lehnert, Pharm.D., BCPS, BCCP</i>	
Introduction	121
Definitions	122
Mechanisms	122
Diagnostic Criteria	125
Clinical Management of AF	125
Contemporary Strategies for Stroke Prevention	138
Contemporary Strategies for Rhythm Control	141
AF Management in Special Populations	148
Conclusion	149
References	149
Self-Assessment Questions	152
 Non-Statin Therapy for Dyslipidemia	
 <i>By Nicholas W. Carris, Pharm.D., BCPS; and Kevin Cowart, Pharm.D., MPH, BCACP, CDCES</i>	
Introduction	157
Populations Likely to Benefit from Non-Statin Therapy	158
Non-Statin Agents for Dyslipidemia	166
Emerging Non-Statin Therapies: Medications in the Pipeline	172
Implementing Non-Statin Therapy	173
Conclusion	174
References	174
Self-Assessment Questions	177
 Cardiology IV	181
Cardiology IV Panel	183
 Interactive Case: Hyperlipidemia Management for Special Populations	
 <i>By Glenn Herrington, Pharm.D., AACC, BCCP, BCPS, CDCES; and Daniel M. Riche, Pharm.D., FCCP, CLS, ASH-CHC</i>	
Interactive Case: Hyperlipidemia Management for Special Populations	187
Hyperlink to activity	188
Self-Assessment Questions	191

Interactive Case: Anticoagulation in Special Populations

*By Allison E. Burnett, Pharm.D., CACP; and Kelly M. Rudd,
Pharm.D., FCCP, BCPS, CACP*

Interactive Case: Anticoagulation in Special Populations	195
Hyperlink to activity	196
Self-Assessment Questions	202

Interactive Case: Cardiovascular Diseases in Pregnancy

By Lindsey Federle, Pharm.D., BCCP, BCPS

Interactive Case: Cardiovascular Diseases in Pregnancy	207
Hyperlink to activity	208
Self-Assessment Questions	210